189 results
Page 5 of 10
8-K
EX-99.1
njt4drxi1odxih m1
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
EX-99.1
z1s6 jbu83l45wrri3n
23 Nov 20
Consolidated Financial Statements
12:00am
8-K/A
EX-99.2
vei lkttg7cmi9uv1z
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
EX-99.1
wx9kuwh5a nz9
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-10.2
lla83qq2q24cqrdfhtx
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-10.3
vsza2c0ma
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-99.1
luvfsp4llu
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
EX-10.4
9y7pt
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
n2zhubbew8p
28 Aug 20
Prospectus supplement
4:31pm
8-K
EX-99.1
ku8s0o h5rdz
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
425
g5ud 8xcvd
24 Jun 20
Business combination disclosure
5:11pm
8-K
EX-2.1
nvcwxxd6n11l6j9
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
EX-10.1
b4pct wnsl7r
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm